These suggested that AS-IV may have protective function on NAFLD rats by downregulating TLR4, MyD 88, and NF-κB expression and inhibiting TNF-α, IL-6, and IL-8 levels. Here, NFKB1 is linked to metabolic dysfunction-associated steatotic liver disease.